Compare AVX & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | FEMY |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 22.4M |
| IPO Year | 2020 | 2021 |
| Metric | AVX | FEMY |
|---|---|---|
| Price | $4.99 | $2.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | ★ 413.7K | 68.9K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | 44.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,340,811.00 | $2,293,313.00 |
| Revenue This Year | $18,042.77 | N/A |
| Revenue Next Year | $12.21 | $328.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3348.10 | 40.77 |
| 52 Week Low | $0.35 | $0.29 |
| 52 Week High | $7.38 | $6.29 |
| Indicator | AVX | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 36.05 |
| Support Level | $4.80 | $2.02 |
| Resistance Level | $6.25 | $3.21 |
| Average True Range (ATR) | 0.73 | 0.15 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 37.49 | 18.67 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.